Supercharged immune cells take on tough lymphoma

NCT ID NCT06120166

Recruiting now Disease control Sponsor: He Huang Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a new kind of CAR-T cell therapy, called Meta10-19, for people with diffuse large B-cell lymphoma that has come back or not responded to treatment. The cells are 'metabolically armed' to give them extra energy to fight cancer. The study will enroll 18 adults to find the safest dose and see if the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metabolically armed CD19 CAR-T cells (Meta10-19)
What this could lead to: If it works, this could point toward a more effective treatment for hard-to-treat lymphoma by boosting the energy of cancer-fighting immune cells.
What could go wrong: This is a very early, small trial (18 people) testing safety and dosing first. The approach may not work or could cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma primary mediastinal large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

The first affiliated hospital of medical college of zhejiang university
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.